NCT03786237 2026-02-24
Rigosertib for RDEB-SCC
Salzburger Landeskliniken
Phase 1/2 Completed
Clinical Trials
17 trialsNCT05764395 2024-10-10
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Suspended
NCT04263090 2024-05-09
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT01926587 2021-06-16
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Traws Pharma, Inc.
Phase 1/2 Completed
NCT02730884 2020-08-07
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01928537 2020-06-30
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Traws Pharma, Inc.
Phase 3 Completed
NCT00861510 2019-12-03
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00854646 2018-01-10
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Traws Pharma, Inc.
Phase 1 Completed
NCT00856791 2017-07-21
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Traws Pharma, Inc.
Phase 2 Completed
NCT00854945 2017-06-26
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Traws Pharma, Inc.
Phase 1/2 Completed
NCT01167166 2017-06-26
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Traws Pharma, Inc.
Phase 1/2 Completed
NCT01807546 2017-06-26
Oral Rigosertib for Squamous Cell Carcinoma
Traws Pharma, Inc.
Phase 2 Completed
NCT00861783 2017-06-23
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Traws Pharma, Inc.
Phase 1 Completed
NCT01165905 2017-06-23
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT01168011 2017-06-23
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT01538563 2017-06-23
Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
Traws Pharma, Inc.
Phase 1 Completed
NCT01360853 2016-08-04
ONTRAC
Traws Pharma, Inc.
Phase 3 Completed